Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca's Seroquel Settlement With DoJ Is Fourth Targeting Antipsychotic Off-Label Promotion; Firm Avoids Criminal Charges

Executive Summary

AstraZeneca's level of cooperation with the Department of Justice's investigation into allegations of off-label promotion for its antipsychotic Seroquel (quetiapine) may have helped shape the final $520 million civil settlement

You may also be interested in...



AstraZeneca Settles Nexium Kickback Suit; Deals Prohibiting Authorized Generic Sales Alleged

AstraZeneca agreed to pay $7.9 million to resolve allegations it paid kickbacks to Medco Health Solutions for preferred formulary placement of Nexium.

CMS Targeting LTC Facility Overprescribing, Citing Antipsychotics

The Centers for Medicare and Medicaid Services is proposing a new Medicare requirement that consulting pharmacists serving long-term care facilities maintain independence from the facility to help avoid drug “overprescribing and overutilization.”

CMS Targeting LTC Facility Overprescribing, Citing Antipsychotics

The Centers for Medicare and Medicaid Services is proposing a new Medicare requirement that consulting pharmacists serving long-term care facilities maintain independence from the facility to help avoid drug “overprescribing and overutilization.”

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel